{"commentary":{"count":67,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":46,"youtube":11,"podcast":10},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05061550\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NeoCOAST-2","nct_id":"NCT05061550","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neocoast-2-nct05061550. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"NeoCOAST-2","arms":[{"description":"Participants will receive Durvalumab + Oleclumab + CTX as neoadjuvant treatment and Durvalumab + Oleclumab as adjuvant treatment.\n\nParticipants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:\n\nCarboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin","label":"Arm 1: Oleclumab + Durvalumab + Platinum doublet chemotherapy (CTX)","type":"EXPERIMENTAL"},{"description":"Participants will receive Durvalumab + Monalizumab + CTX as neoadjuvant treatment and Durvalumab + Monalizumab as adjuvant treatment.\n\nParticipants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:\n\nCarboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin","label":"Arm 2: Monalizumab + Durvalumab + CTX","type":"EXPERIMENTAL"},{"description":"Participants will receive Volrustomig + CTX as neoadjuvant treatment and Volrustomig as adjuvant treatment.\n\nParticipants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:\n\nCarboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin","label":"Arm 3: Volrustomig (Dose Exploration) + CTX","type":"EXPERIMENTAL"},{"description":"Participants will receive Dato-DXd + durvalumab + single agent platinum as neoadjuvant treatment and durvalumab as adjuvant treatment.\n\nParticipants will receive one of the following chemotherapy regimens, based on physician choice of as part of their treatment regimen prior to surgery:\n\nCarboplatin or Cisplatin","label":"Arm 4: Dato-DXd + durvalumab + single agent platinum","type":"EXPERIMENTAL"},{"description":"Participants will receive AZD0171 + durvalumab + CTX as neoadjuvant treatment and AZD0171 + durvalumab as adjuvant treatment.\n\nParticipants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:\n\nCarboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin","label":"Arm 5: AZD0171 + durvalumab + CTX","type":"EXPERIMENTAL"},{"description":"Participants will receive Rilvegostomig + CTX as neoadjuvant treatment and Rilvegostomig as adjuvant treatment.\n\nParticipants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:\n\nCarboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin","label":"Arm 6: Rilvegostomig + CTX","type":"EXPERIMENTAL"},{"description":"Participants will receive Dato-DXd + Rilvegostomig + single agent platinum as neoadjuvant treatment and Rilvegostomig as adjuvant treatment.\n\nParticipants will receive one of the following chemotherapy regimens, based on physician choice of as part of their treatment regimen prior to surgery:\n\nCarboplatin or Cisplatin","label":"Arm 7: Dato-DXd + Rilvegostomig + single agent platinum","type":"EXPERIMENTAL"}],"collaborators":["Parexel"],"completion_date":{"date":"2030-05-28","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":630,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Durvalumab","type":"DRUG"},{"name":"Oleclumab","type":"DRUG"},{"name":"Monalizumab","type":"DRUG"},{"name":"Dato-DXd","type":"DRUG"},{"name":"AZD0171","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Pemetrexed/Cisplatin","type":"DRUG"},{"name":"Pemetrexed/Carboplatin","type":"DRUG"},{"name":"Carboplatin/Paclitaxel","type":"DRUG"},{"name":"Volrustomig","type":"DRUG"},{"name":"Rilvegostomig","type":"DRUG"}],"last_update":"2026-09-23","lead_sponsor":"AstraZeneca","official_title":"A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2030-05-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants with pathological complete response (pCR)","timeFrame":"From randomization to approximately 15 weeks after the first dose of study interventions"},{"measure":"Number of participants with adverse events (AEs) and serious adverse events (SAEs)","timeFrame":"Until Day 90 after the last dose of study interventions (Up to approximately 3 years)"}],"references":[{"citation":"Cascone T, Bonanno L, Guisier F, Insa A, Liberman M, Bylicki O, Livi L, Egenod T, Corre R, Kim DW, Garcia Campelo MR, Provencio Pulla M, Shim BY, Metro G, Bennouna J, Bielska AA, Yohannes AR, He Y, Dowson A, Kar G, McGrath L, Kumar R, Grenga I, Spicer J, Forde PM. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial. Nat Med. 2025 Aug;31(8):2788-2796. doi: 10.1038/s41591-025-03746-z. Epub 2025 May 31.","pmid":"40450142","type":"DERIVED"}],"start_date":{"date":"2022-04-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05061550"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neocoast-2-nct05061550"}